| Home | << 1 2 3 4 5 6 7 8 9 10 >> [11–15] |
|
Richard, J. M., Valcarce, A., & Vijande, J. (2017). String dynamics and metastability of all-heavy tetraquarks. Phys. Rev. D, 95(5), 054019–7pp.
Abstract: Multiquark states have been advocated to explain recent experimental data in the heavy-light sector, and there are already speculations about multiquarks containing only heavy quarks and antiquarks. With a rigorous treatment of the four-body problem in current quark models, full-charm (cc (c) over bar(c) over bar) and full-beauty(bb (b) over bar(b) over bar) tetraquarks are found to be unbound. Thus their stability should rely on more subtle effects that are not included in the simple picture of constituent quarks. The case of (bc (b) over bar(c) over bar) might be more favorable if the naive color-additive model of confinement is replaced by a string-inspired interaction.
|
|
Hueso-Gonzalez, F., Ballester, F., Perez-Calatayud, J., Siebert, F. A., & Vijande, J. (2017). Towards clinical application of RayStretch for heterogeneity corrections in LDR permanent I-125 prostate brachytherapy. Brachytherapy, 16(3), 616–623.
Abstract: PURPOSE: RayStretch is a simple algorithm proposed for heterogeneity corrections in low-dose-rate brachytherapy. It is built on top of TG-43 consensus data, and it has been validated with Monte Carlo (MC) simulations. In this study, we take a real clinical prostate implant with 71 1251 seeds as reference and we apply RayStretch to analyze its performance in worst-case scenarios. METHODS AND MATERIALS: To do so, we design two cases where large calcifications are located in the prostate lobules. RayStretch resilience under various calcification density values is also explored. Comparisons against MC calculations are performed. RESULTS: Dose volume histogram related parameters like prostate D-90, rectum D-2cc, or urethra D-10 obtained with RayStretch agree within a few percent with the detailed MC results for all cases considered. CONCLUSIONS: The robustness and compatibility of RayStretch with commercial treatment planning systems indicate its applicability in clinical practice for dosimetric corrections in prostate calcifications. Its use during intraoperative ultrasound planning is foreseen.
Keywords: Brachytherapy; Low-dose rate; Heterogeneities; Prostate; Calcifications; Dosimetry
|
|
Garcilazo, H., Valcarce, A., & Vijande, J. (2017). (4)(Lambda Lambda) n system. Chin. Phys. C, 41(7), 074102–6pp.
Abstract: Using local central Yukawa-type Malfliet-Tjon interactions reproducing the low-energy parameters and phase shifts of the nn system, and the latest updates of the n Lambda and Lambda Lambda Nijmegen ESCO8c potentials, we study the possible existence of a (4)(Lambda Lambda)n bound state. Our results indicate that the (4)(Lambda Lambda)n is unbound, being just above threshold. We discuss the role played by the S-1(0) nn repulsive term of the Yukawa-type Malfliet-Tjon interaction.
Keywords: baryon-baryon interactions; few-body systems
|
|
Garcilazo, H., Valcarce, A., & Vijande, J. (2017). Stable bound states of N's, Lambda's and Xi's. Rev. Mex. Fis., 63(5), 411–422.
Abstract: We review our recent work about the stability of strange few-body systems containing N's, Lambda's, and Xi's. We make use of local central Yukawa-type Malfliet-Tjon interactions reproducing the low-energy parameters and phase shifts of the nucleon-nucleon system and the latest updates of the hyperon-nucleon and hyperon-hyperon ESCO8c Nijmegen potentials. We solve the three-and four-body bound-state problems by means of Faddeev equations and a generalized Gaussian variational method, respectively. The hypertriton, Lambda np(I)J(P) = (1/2)1/2(+), is bound by 144 keV; the recently discussed Lambda nn (I)J(P) = (1/2)1/2(+) system is unbound, as well as the Lambda Lambda nn (I)J(P) = (1)0(+) system, being just above threshold. Our results indicate that the Xi NN, Xi Xi N and Xi Xi NN systems with maximal isospin might be bound.
|
|
Ma, Y. Z., Vijande, J., Ballester, F., Tedgren, A. C., Granero, D., Haworth, A., et al. (2017). A generic TG-186 shielded applicator for commissioning model-based dose calculation algorithms for high-dose-rate Ir-192 brachytherapy. Med. Phys., 44(11), 5961–5976.
Abstract: PurposeA joint working group was created by the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), and the Australasian Brachytherapy Group (ABG) with the charge, among others, to develop a set of well-defined test case plans and perform calculations and comparisons with model-based dose calculation algorithms (MBDCAs). Its main goal is to facilitate a smooth transition from the AAPM Task Group No. 43 (TG-43) dose calculation formalism, widely being used in clinical practice for brachytherapy, to the one proposed by Task Group No. 186 (TG-186) for MBDCAs. To do so, in this work a hypothetical, generic high-dose rate (HDR) Ir-192 shielded applicator has been designed and benchmarked. MethodsA generic HDR Ir-192 shielded applicator was designed based on three commercially available gynecological applicators as well as a virtual cubic water phantom that can be imported into any DICOM-RT compatible treatment planning system (TPS). The absorbed dose distribution around the applicator with the TG-186 Ir-192 source located at one dwell position at its center was computed using two commercial TPSs incorporating MBDCAs (Oncentra((R)) Brachy with Advanced Collapsed-cone Engine, ACE, and BrachyVision ACUROS) and state-of-the-art Monte Carlo (MC) codes, including ALGEBRA, BrachyDose, egs_brachy, Geant4, MCNP6, and Penelope2008. TPS-based volumetric dose distributions for the previously reported source centered in water and source displaced test cases, and the new source centered in applicator test case, were analyzed here using the MCNP6 dose distribution as a reference. Volumetric dose comparisons of TPS results against results for the other MC codes were also performed. Distributions of local and global dose difference ratios are reported. ResultsThe local dose differences among MC codes are comparable to the statistical uncertainties of the reference datasets for the source centered in water and source displaced test cases and for the clinically relevant part of the unshielded volume in the source centered in applicator case. Larger local differences appear in the shielded volume or at large distances. Considering clinically relevant regions, global dose differences are smaller than the local ones. The most disadvantageous case for the MBDCAs is the one including the shielded applicator. In this case, ACUROS agrees with MC within [-4.2%, +4.2%] for the majority of voxels (95%) while presenting dose differences within [-0.12%, +0.12%] of the dose at a clinically relevant reference point. For ACE, 95% of the total volume presents differences with respect to MC in the range [-1.7%, +0.4%] of the dose at the reference point. ConclusionsThe combination of the generic source and generic shielded applicator, together with the previously developed test cases and reference datasets (available in the Brachytherapy Source Registry), lay a solid foundation in supporting uniform commissioning procedures and direct comparisons among treatment planning systems for HDR Ir-192 brachytherapy.
|